Walleye Capital LLC Pharvaris N.V. Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$15.67 - $24.59 $758,647 - $1.19 Million	-48,414 Reduced 49.82%	48,768 $916,000
Q1 2024 May 15, 2024	BUY	$21.26 - $32.07 $410,573 - $619,335	19,312 Added 24.8%	97,182 $2.25 Million
Q4 2023 Feb 14, 2024	SELL	$15.2 - $28.05 $47,834 - $88,273	-3,147 Reduced 3.88%	77,870 $2.18 Million
Q3 2023 Nov 14, 2023	BUY	$14.68 - $21.4 $156,943 - $228,787	10,691 Added 15.2%	81,017 $1.69 Million
Q2 2023 Aug 14, 2023	SELL	$7.82 - $16.0 $309,820 - $633,904	-39,619 Reduced 36.04%	70,326 $1.06 Million
Q1 2023 May 15, 2023	SELL	$6.34 - $12.27 $262,374 - $507,781	-41,384 Reduced 27.35%	109,945 $885,000
Q4 2022 Feb 14, 2023	BUY	$1.98 - $11.46 $299,631 - $1.73 Million	151,329 New	151,329 $1.7 Million

39.6M

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $687M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.